Ornisid - description of the drug, instructions for use, reviews

Write a review

Reviews: 0

Manufacturers: Abdi Ibrahim Ilac Sanayi ve Ticaret AS (Türkiye)

Active ingredients

• Ornidazole

Disease class

• Amoebiasis
• Acute amoebic dysentery
• Amoebic liver abscess
• Amebic infection of another location
• Giardiasis (giardiasis)
• Trichomoniasis
• Surgical practice

Clinical and pharmacological group

• Not indicated. See instructions

Pharmacological action

• Antiprotozoal
• Antibacterial

Pharmacological group

• Other synthetic antibacterial agents

Composition and release form

Ornisid is available in tablets for oral administration and in the form of suppositories for vaginal administration. The active ingredient is ornidazole. Ornisid tablets contain 250 mg or 500 mg (Ornisid forte) of the active substance. Ornisid vaginal suppositories contain 500 mg of ornidazole.

In addition to the active substance, Ornisid tablets contain auxiliary components: microcrystalline cellulose, potato starch, magnesium stearate, hydroxymethylethylcellulose. Auxiliary components of vaginal suppositories include lactose, dihydrogen phosphate, anhydrous citric acid, magnesium stearate, PVP, gelatinized starch, corn starch.

Ornisid tablets (250 mg) are available in blister packs of 20 pieces, one blister in a cardboard package. Ornisid forte tablets (500 mg) are available in blister packs of 10 tablets, 1 blister in a cardboard package. Ornisid vaginal suppositories are available in blister packs of 3 pieces.

Price

Average price in Russia

Ornisid 250 mg tablets No. 20 cost from 55 to 85 rubles. per pack. You can purchase them at any pharmacy chain without much difficulty.

Average cost in Ukraine

Residents of Ukraine can also buy Ornisid. The cost of the medicine in most pharmacies is 23-57 hryvnia.

All gastroenterology clinics and medical centers in your city. Tests and ultrasound. Consultation with a gastroenterologist. Diseases of the digestive system. Find out more: - In Kiev (Hertz, Ilaya, Euromed) - In St. Petersburg (SM-Clinic, Longevity, Allergomed, Doctor +, BaltZdrav, Professor) - In Moscow (SM-Clinic, Medlux, Onmed) - In Kharkov ( TsMEI, Olympic, Victoria, Fortis, Ecomed) - In Minsk (Belgirudo, Art-Med-Company, Sinlab, Mikosha, GrandMedica, MedClinic) - in Odessa (Medea, On Clinic, Into Sano, Venus) - In Razyan (Trust + , Polyclinic-Pesochnya, Evrikas +) - in Nizhny Novgorod (Only Clinic, Alpha Center, EuroClinic, SOLO, Altea) - gastroenterological clinics of Tyumen (Doctor A+, Clinic "Vera", Avicenna, Medis, Sibirina, Your Doctor)

Pharmacological action of Ornisid

According to the instructions, Ornisid has antibacterial and antiprotozoal effects. Ornizadol is a derivative of 5-nitroimidazole; it inhibits the synthesis of bacterial DNA and thus leads to the death of microorganisms.

Ornisid is active against Trichomonas, dysenteric amoeba, Giardia, Gardenerella, as well as against some anaerobic microorganisms (bacteroides, some clostridia, fusobacteria, anaerobic cocci). Aerobic microorganisms are not sensitive to this drug.

After oral administration, Ornisid is quickly absorbed according to the instructions, the bioavailability of the drug is high (90%), the maximum concentration in the blood after oral administration is observed after 1-2 hours.

According to the instructions, Ornisid is excreted primarily by the kidneys (about 70%) and intestines (25%). The drug penetrates the blood-brain barrier, the placenta and into breast milk.

Similar drugs:

• Furacilin Solution for topical use
• Lactobacterin siccum dry (Lactobacterin siccum) Lyophilisate for the preparation of solution for oral administration
• Palin Capsule
• Bactrim Oral suspension
• Nitroxoline Oral tablets
• Pancef Oral tablets
• Nifuroxazide (Nifuroxazide) Oral tablets
• Ercefuryl Oral suspension
• Sextaphag Oral solution
• Pancef Granules for the preparation of suspension for oral administration

** The Drug Directory is intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; Before starting to use the drug Ornisid, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace medical advice and cannot serve as a guarantee of the positive effect of the drug.

Are you interested in the drug Ornisid? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.

** Attention! The information presented in this medication guide is intended for medical professionals and should not be used as a basis for self-medication. The description of the drug Ornisid is provided for informational purposes and is not intended for prescribing treatment without the participation of a doctor. Patients need to consult a specialist!

If you are interested in any other drugs and medications, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, methods of use, prices and reviews of drugs, or you have any other questions and suggestions - write to us, we will definitely try to help you.

Contraindications to the use of Ornisid

Ornisid tablets are contraindicated in case of hypersensitivity to the constituent components of the drug, signs of liver failure, organic diseases of the nervous system, as well as in the first 12 weeks of pregnancy (first trimester) and during breastfeeding.

Ornisid vaginal suppositories are contraindicated in case of hypersensitivity to the constituent components of this drug, as well as in case of leukopenia, organic diseases of the nervous system (including epilepsy), during the first trimester of pregnancy and during breastfeeding.

According to the instructions, Ornisid should be used with caution in the second and third trimesters of pregnancy, and in patients with a history of leukopenia.

Side effects

Taking Ornisid may cause undesirable reactions such as tremor, disturbances of consciousness, headaches, rigidity, dizziness, convulsions, incoordination, nausea, sensory or mixed peripheral neuropathy, diarrhea, vomiting.

Overdose

As with other drugs, exceeding doctor-recommended doses can cause an overdose with characteristic symptoms: depression, epileptiform seizures, peripheral neuritis.

Therapy in this case is symptomatic. A patient with seizures can be treated without leaving home. To do this, it is enough to give the patient Diazepam.

Contraindications

The tablet form of the drug is not used for liver failure (when prescribing large doses), hypersensitivity, breastfeeding, organic diseases of the central nervous system, pregnancy (trimester 1).

Vaginal suppositories are contraindicated in case of leukopenia, pregnancy (1st trimester), impaired coordination of movements, breastfeeding, organic lesions of the central nervous system (including epilepsy), hypersensitivity to the components of the drug (including nitroimidazole derivatives).

The manufacturer of the drug notes: you need to be extremely careful when prescribing the medicine to people with previous leukopenia and pregnant patients (third, second trimesters).

During pregnancy

It is strictly forbidden to take Ornisid during the first trimester. Vaginal suppositories can be used in the third and second trimesters, but with caution and under the supervision of a doctor . If treatment with Ornisid is required by a nursing woman, she should stop breastfeeding for the duration of therapy.

Method of administration and dosage of Ornisid

Ornisid tablets (250 mg) for trichomoniasis are prescribed 2 times a day, 500 mg, the course of treatment for this disease is 5 days. For children, the dosage of the drug is calculated based on the child’s weight (25 mg/kg/day).

For anaerobic infections, Ornisid is recommended to be used at a dose of 500 mg 2 times a day.

For amoebic dysentery, this drug is prescribed 1.5-2 g once a day. For children, the dosage is calculated based on the formula 40 mg/kg/day. Duration of treatment – ​​3 days.

When treating giardiasis, Ornisid is prescribed 1.5 g per day; for children, the dose is calculated using the formula 40 mg/kg/day. The course of treatment is 1-2 days.

To prevent anaerobic infections, a single dose of Ornisid is recommended at a dose of 500-1000 mg before surgery, and after surgery, 500 mg 2 times a day for 3-5 days.

Ornisid vaginal suppositories should be inserted deep into the vagina after preliminary hygienic treatment of the external genital area.

For trichomoniasis, 1 Ornisid suppository is prescribed at night. Typically, intravaginal use is combined with oral tablets of this drug (1.5 g once or 1 g per day for 5 days).

Reviews

Most people whose reviews are available on forums speak about the drug in a positive way. Judging by the diagnoses given to these patients, Ornisid is most often prescribed in the complex treatment of various infectious pathologies of the urogenital area, i.e. in combination with vaginal tablets (suppositories).

If you want to read all the reviews about Ornisis, go to the end of the article.

If you have already had experience using the medicine, share your opinion about the drug. Site visitors will be extremely grateful to you.

Ornisid Forte 500 mg No. 10 tablet p.o.

Instructions for medical use of the drug ORNISID® forte Trade name Ornisid® forte International nonproprietary name Ornidazole Dosage form Film-coated tablets 500 mg Composition One tablet contains the active substance - ornidazole 500 mg excipients: microcrystalline cellulose (Type 102), corn starch, hydroxypropyl methylcellulose (E-15), magnesium stearate coating composition: Oradry II 85F18422 White (polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol/PEG (MW 3350) (E1521), talc) Description Film-coated tablets, white or yellowish-white in color, round in shape with a biconvex surface, with a mark on one side. Pharmacotherapeutic group Drugs for the treatment of amoebiasis and other protozoal infections. Nitroimidazole derivatives. Ornidazole ATC code P01AB03 Pharmacological properties Pharmacokinetics Ornidazole is easily absorbed from the gastrointestinal tract. Bioavailability – 90%. The maximum concentration in blood plasma is achieved within 2 hours. After oral administration of a maximum daily dose of 1.5 g, the concentration of ornidazole in the blood plasma reaches 30 mg/ml; after 24 hours, the plasma concentration decreases to 9 mg/ml. Plasma protein binding is less than 15%. Ornidazole penetrates well into all tissues and fluids of the body, including cerebrospinal fluid. Biotransformation of ornidazole occurs in the liver. The half-life of ornidazole is 12-14 hours. After a single dose, 85% of the dose is excreted from the body within 5 days in the form of metabolites. Ornidazole is excreted mainly in the form of metabolites by the kidneys (63%) and excrement (22%). Elimination of ornidazole is also possible through the bile route. Pharmacodynamics Ornisid (ornidazole) has antibacterial and antiprotozoal effects. Interacting with the DNA of a microbial cell, it causes disruption of its helical structure, rupture of threads, suppresses the synthesis of nucleic acids and causes the death of microbial cells and protozoan cells. Ornisid (ornidazole) is active against protozoa: Trichomonas vaginalis, Entamoeba histolitica, Gardnerella vaginalis, Giardia intestinalis, Lambilia. And also in relation to anaerobic cocci: Peptostrepococcus, Peptococcus. Indications for use - trichomoniasis in women and men: trichomonas vulvovaginitis, urethritis, bartholenitis, cervicitis, prostatitis, adnexitis - amebiasis: amoebic dysentery, extraintestinal amebiasis (including amoebic liver abscess) - giardiasis - prevention of anaerobic infections during surgical interventions, on the colon intestine and gynecology Method of administration and dosage Tablets are taken after meals. In the treatment of trichomoniasis in adults, two combination therapy regimens are used. Course of treatment: 1 regimen 2 regimen Single dose 1.5 g (3 tablets) orally 1 g (2 tablets) orally + 1 vaginal tablet. (Ornisida) before bedtime 5 days 500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening orally 500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening orally + 1 vaginal tablet. (Ornisida) before bedtime For children, the dose is set at the rate of 25 mg/kg body weight/day. For amoebic dysentery, adults and children weighing more than 35 kg are prescribed orally 1.5 g (3 tablets) 1 time/day. In the evening; adults weighing more than 60 kg – 2g/day. (2 tablets in the morning and 2 tablets in the evening). For children weighing less than 35 kg, the drug is prescribed 1 time/day at the rate of 40 mg/kg body weight. The course of treatment is 3 days. For other forms of amebiasis, adults and children weighing more than 35 kg are prescribed 500 mg orally 2 times a day (1 tablet in the morning and 1 tablet in the evening). The course of treatment is 5-10 days. For giardiasis, adults and children weighing more than 35 kg are prescribed orally 1.5 g (3 tablets) 1 time/day. in the evening for 1-2 days, or 500 mg 2 times a day (1 tablet in the morning and 1 tablet in the evening) for 5-10 days. For children weighing less than 35 kg, the drug is prescribed 1 time/day at the rate of 40 mg/kg body weight when taken for 1-2 days. Prevention of infections caused by anaerobic bacteria - 0.5-1 g before surgery, after surgery - 0.5 g 2 times a day for 3-5 days. The daily dose for children is set at 25 mg/kg body weight. Side effects Disorders of the blood and lymphatic system Rarely (≥1/10,000, but <1/1000): - Leukopenia Disorders of the nervous system Very rare (<1/10,000): - drowsiness - headache - dizziness - tremor - rigidity - incoordination - convulsions - fatigue - vertigo - temporary loss of consciousness - sensory or mixed peripheral neuropathy Gastrointestinal disorders Uncommon (≥1/1000, but <1/100): - nausea - vomiting - diarrhea - unpleasant feeling in the epigastric region - dry mouth - anorexia Rarely (≥1/10,000, but <1/1000): - taste disturbances Liver and biliary tract disorders Unknown (impossible to estimate based on available data): - bile spillage - abnormal liver function indicators Disturbances of the skin and subcutaneous tissues are rare (≥1/10,000, but <1/1000) - itching and skin reactions Contraindications - hypersensitivity to the components of the drug - organic diseases of the central nervous system - pregnancy and lactation - childhood up to 6 years Drug interactions When Ornisid is used together with other 5-nitroimidazole derivatives, peripheral neuropathy, depression and epileptoform seizures may occur. Ornidazole does not inhibit aldehyde dehydrogenase and therefore does not interact with alcohol. Concomitant use with microsomal enzyme inducers (barbiturates, benzodiazepines, rifampicins, etc.) reduces the half-life of ornidazole in serum. Inhibitors of microsomal enzymes (cimetidine, macrolides, etc.) increase the half-life of ornidazole. Ornidazole enhances the effect of anticoagulants, which requires adjustment of their dose. The combination of orniside with neurotoxic and hematotoxic drugs is not recommended. Extends the muscle relaxant effect of vecuronium bromide Special instructions Use with caution in diseases of the central nervous system (including epilepsy, multiple sclerosis); liver diseases and alcoholism. For trichomoniasis, simultaneous treatment of the sexual partner should be carried out to avoid re-infection. Features of the effect of the drug on the ability to drive a car or potentially dangerous mechanisms Considering the possibility of developing side effects from the central nervous system, care should be taken when driving vehicles and potentially dangerous mechanisms. Overdose Symptoms: increased side effects. Treatment: there is no antidote, symptomatic therapy is carried out, diazepam is prescribed for convulsions. Release form and packaging 10 tablets are placed in a blister pack made of polyvinyl chloride film and aluminum foil. 1 contour package together with instructions for medical use in the state and Russian languages ​​are placed in a cardboard box. Storage conditions Store in a dry place, protected from light, at a temperature not exceeding 25 0C. Keep out of the reach of children! Shelf life 3 years Do not use after the expiration date indicated on the package. Conditions for dispensing from pharmacies By prescription, Istanbul, Turkey Registration certificate holder “ABDI IBRAHIM”, Istanbul, Turkey